Ryvu Therapeutics S.A. (RVU.WA)
PLN 28.4
(4.03%)
PLN 28.4
(4.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 46.86 Million PLN | 20.76% |
| 2022 | 38.8 Million PLN | 246.89% |
| 2021 | 11.18 Million PLN | -27.43% |
| 2020 | 15.41 Million PLN | -63.79% |
| 2019 | 42.56 Million PLN | -44.87% |
| 2018 | 77.2 Million PLN | -12.09% |
| 2017 | 87.82 Million PLN | 82.45% |
| 2016 | 48.13 Million PLN | 17.32% |
| 2015 | 41.02 Million PLN | 42.14% |
| 2014 | 28.86 Million PLN | 119.45% |
| 2013 | 13.15 Million PLN | 39.63% |
| 2012 | 9.41 Million PLN | 4.46% |
| 2011 | 9.01 Million PLN | 1.94% |
| 2010 | 8.84 Million PLN | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 21.6 Million PLN | 93.0% |
| 2024 Q2 | 15.74 Million PLN | -27.13% |
| 2023 Q2 | 10.75 Million PLN | -16.34% |
| 2023 Q1 | 12.86 Million PLN | -47.46% |
| 2023 FY | 46.86 Million PLN | 20.76% |
| 2023 Q4 | 11.19 Million PLN | -7.06% |
| 2023 Q3 | 12.04 Million PLN | 11.95% |
| 2022 Q3 | 14.26 Million PLN | 5331.58% |
| 2022 Q1 | 31.63 Thousand PLN | -99.69% |
| 2022 Q2 | 262.61 Thousand PLN | 730.02% |
| 2022 FY | 38.8 Million PLN | 246.89% |
| 2022 Q4 | 24.47 Million PLN | 71.6% |
| 2021 Q4 | 10.15 Million PLN | 3411.25% |
| 2021 Q1 | 273.75 Thousand PLN | 9.72% |
| 2021 FY | 11.18 Million PLN | -27.43% |
| 2021 Q2 | 309.55 Thousand PLN | 13.08% |
| 2021 Q3 | 289.23 Thousand PLN | -6.56% |
| 2020 Q4 | 249.5 Thousand PLN | -44.49% |
| 2020 FY | 15.41 Million PLN | -63.79% |
| 2020 Q1 | 7.77 Million PLN | -80.28% |
| 2020 Q2 | 6.94 Million PLN | -10.72% |
| 2020 Q3 | 449.46 Thousand PLN | -93.52% |
| 2019 Q1 | 20.66 Million PLN | 0.46% |
| 2019 Q4 | 39.41 Million PLN | 3140.76% |
| 2019 FY | 42.56 Million PLN | -44.87% |
| 2019 Q3 | 1.21 Million PLN | -94.67% |
| 2019 Q2 | 22.82 Million PLN | 10.45% |
| 2018 Q3 | 19.38 Million PLN | 0.06% |
| 2018 Q4 | 20.56 Million PLN | 6.11% |
| 2018 FY | 77.2 Million PLN | -12.09% |
| 2018 Q2 | 19.37 Million PLN | 8.37% |
| 2018 Q1 | 17.87 Million PLN | -7.16% |
| 2017 FY | 87.82 Million PLN | 82.45% |
| 2017 Q3 | 16.96 Million PLN | -54.44% |
| 2017 Q1 | 14.34 Million PLN | 3.54% |
| 2017 Q2 | 37.24 Million PLN | 159.56% |
| 2017 Q4 | 19.25 Million PLN | 13.48% |
| 2016 Q1 | 11.39 Million PLN | -15.41% |
| 2016 FY | 48.13 Million PLN | 17.32% |
| 2016 Q4 | 13.85 Million PLN | 19.38% |
| 2016 Q3 | 11.6 Million PLN | 2.98% |
| 2016 Q2 | 11.27 Million PLN | -1.04% |
| 2015 Q4 | 13.46 Million PLN | 30.51% |
| 2015 Q3 | 10.31 Million PLN | 16.71% |
| 2015 Q2 | 8.84 Million PLN | 5.21% |
| 2015 Q1 | 8.4 Million PLN | -5.18% |
| 2015 FY | 41.02 Million PLN | 42.14% |
| 2014 Q1 | 5.04 Million PLN | 0.77% |
| 2014 Q4 | 8.86 Million PLN | 17.91% |
| 2014 Q3 | 7.51 Million PLN | 0.95% |
| 2014 Q2 | 7.44 Million PLN | 47.71% |
| 2014 FY | 28.86 Million PLN | 119.45% |
| 2013 Q4 | 5 Million PLN | 61.4% |
| 2013 FY | 13.15 Million PLN | 39.63% |
| 2013 Q1 | 2.28 Million PLN | 6.44% |
| 2013 Q2 | 2.76 Million PLN | 20.69% |
| 2013 Q3 | 3.09 Million PLN | 12.18% |
| 2012 Q3 | 2.93 Million PLN | 29.06% |
| 2012 FY | 9.41 Million PLN | 4.46% |
| 2012 Q2 | 2.27 Million PLN | 10.47% |
| 2012 Q1 | 2.05 Million PLN | 0.0% |
| 2012 Q4 | 2.15 Million PLN | -26.74% |
| 2011 FY | 9.01 Million PLN | 1.94% |
| 2010 FY | 8.84 Million PLN | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioceltix S.A. | - PLN | -Infinity% |
| BIOTON S.A. | 181.63 Million PLN | 74.201% |
| Captor Therapeutics Spolka Akcyjna | 13.2 Million PLN | -254.973% |
| Mabion S.A. | 151.67 Million PLN | 69.106% |
| Molecure S.A. | 100.00 PLN | -46859900.0% |
| NanoGroup S.A. | 2019.00 PLN | -2320850.966% |
| Pharmena S.A. | 9.83 Million PLN | -376.365% |
| Poltreg S.A. | 1.39 Million PLN | -3249.535% |
| Pure Biologics Spólka Akcyjna | 95 Thousand PLN | -49226.316% |
| Synthaverse S.A. | 58.6 Million PLN | 20.044% |
| Urteste S.A. | - PLN | -Infinity% |